Biote Investors Sue Cooley, SPAC After Huge Merger Loss

By Katryna Perera

Family trust investors in Biote Corp. have sued Cooley LLP and the "hormone optimization" company's top brass over the $700 million merger Biote completed with a special purpose acquisition company, saying the deal was a "disastrous transaction to divert approximately $70 million of merger consideration to themselves and gain control of an enterprise they did not build."

Read full article » | Save to favorites »